Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05591118 · ClinicalTrials.gov registry record · Phase 3
Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy
A Phase 3 study of Pulmonary Embolism, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 500
- Enrollment target
- 20
- Study locations
NCT05591118: Recruiting Phase 3 study of Pulmonary Embolism, sponsored by NYU Langone Health.
NCT05591118 is a Phase 3 study of Pulmonary Embolism that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 500 participants, below the 3,048-participant average among 48 other Pulmonary Embolism trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05591118, a Phase 3 study of Pulmonary Embolism, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
PE-TRACT is an open-label, assessor-blinded, randomized trial, aiming to compare catheter-directed therapy (CDT) and anticoagulation (CDT group) with anticoagulation alone (No-CDT) in 500 patients with submassive PE, proximal pulmonary artery thrombus and right ventricular dilation.
Primary Outcome
PVO2 measured during cardiopulmonary exercise test (CPET).
Conditions Studied
Interventions
- DRUG Anticoagulant Therapy
- DEVICE Catheter-Directed Therapy
Study Locations (20)
California
- Stanford Medicine - Palo Alto
- UC Davis Health - Sacramento
- Scripps Memorial Hospital, La Jolla - San Diego
- The Lundquist Institute - Torrance
Illinois
- University of Chicago Medical Center - Chicago
- Advocate Good Samaritan Hospital - Downers Grove
- Loyola University Chicago - Maywood
- Southern Illinois University School of Medicine - Springfield
Florida
- Baptist Health Miami Cardiac & Vascular Institute - Miami
- University of South Florida/ Tampa General Hospital - Tampa
Massachusetts
- Boston Medical Center - Boston
- Beth Israel Deaconess Medical Center - Boston
Michigan
- University of Michigan - Ann Arbor
- Trinity Health - Ann Arbor Hospital - Ypsilanti
Alabama
- The University of Alabama At Birmingham - Birmingham
Delaware
- Christiana Care - Newark
District of Columbia
- MedStar Health Research Institute - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2023-07-17 |
| Est. Completion | 2027-06-26 |
| Phase | Phase 3 |
What NCT05591118 shows while recruiting
NCT05591118 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 3,048-participant average among 48 other Pulmonary Embolism trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Pulmonary Embolism appearing as the primary indexed condition, and to 2 interventions - of which Anticoagulant Therapy is the first listed.
NCT05591118 names 20 study sites across 11 states, led by California, Illinois, Florida.
Frequently Asked Questions
What is clinical trial NCT05591118 about?
NCT05591118 is a clinical study titled "Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy". PE-TRACT is an open-label, assessor-blinded, randomized trial, aiming to compare catheter-directed therapy (CDT) and anticoagulation (CDT group) with anticoagulation alone (No-CDT) in 500 patients with submassive PE, proximal pulmonary artery thrombus and right ventricular dilation.
What is the current status of trial NCT05591118?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2023-07-17. Estimated completion is 2027-06-26.
What conditions does trial NCT05591118 study?
This clinical trial studies the following conditions: Pulmonary Embolism.
What interventions are being tested in trial NCT05591118?
The interventions under investigation include: Anticoagulant Therapy (DRUG), Catheter-Directed Therapy (DEVICE).
Who is sponsoring clinical trial NCT05591118?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05591118 being conducted?
This trial has 20 study locations across Alabama, California, Delaware, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Embolism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05591118's enrollment target sits among peer trials
500 13th of 48 higher than 36 of 48 other Pulmonary Embolism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Embolism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
ACTIVE NOT RECRUITING · Phase 3
-
Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
COMPLETED · Phase 3
-
tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden
COMPLETED · Phase 3
-
A Study of Mobility Outcomes in Post-Pulmonary Embolic Disease
RECRUITING · NA
-
Intervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer Surgery
RECRUITING · NA
-
Clinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI